JP2019535645A5 - - Google Patents

Download PDF

Info

Publication number
JP2019535645A5
JP2019535645A5 JP2019513898A JP2019513898A JP2019535645A5 JP 2019535645 A5 JP2019535645 A5 JP 2019535645A5 JP 2019513898 A JP2019513898 A JP 2019513898A JP 2019513898 A JP2019513898 A JP 2019513898A JP 2019535645 A5 JP2019535645 A5 JP 2019535645A5
Authority
JP
Japan
Prior art keywords
chimeric polypeptide
cell
polypeptide according
seq
amino acid
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2019513898A
Other languages
English (en)
Japanese (ja)
Other versions
JP2019535645A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2017/050787 external-priority patent/WO2018049237A1/en
Publication of JP2019535645A publication Critical patent/JP2019535645A/ja
Publication of JP2019535645A5 publication Critical patent/JP2019535645A5/ja
Pending legal-status Critical Current

Links

JP2019513898A 2016-09-09 2017-09-08 ラフォラ病の処置のための方法及び組成物 Pending JP2019535645A (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201662385656P 2016-09-09 2016-09-09
US62/385,656 2016-09-09
US201762553048P 2017-08-31 2017-08-31
US62/553,048 2017-08-31
PCT/US2017/050787 WO2018049237A1 (en) 2016-09-09 2017-09-08 Methods and compositions for treatment of lafora disease

Publications (2)

Publication Number Publication Date
JP2019535645A JP2019535645A (ja) 2019-12-12
JP2019535645A5 true JP2019535645A5 (enExample) 2020-10-22

Family

ID=61562328

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2019513898A Pending JP2019535645A (ja) 2016-09-09 2017-09-08 ラフォラ病の処置のための方法及び組成物

Country Status (7)

Country Link
US (1) US10781433B2 (enExample)
EP (1) EP3509614A4 (enExample)
JP (1) JP2019535645A (enExample)
CN (1) CN109963576A (enExample)
AU (1) AU2017322483A1 (enExample)
CA (1) CA3036524A1 (enExample)
WO (1) WO2018049237A1 (enExample)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2744840T3 (es) 2011-04-01 2020-02-26 Univ Yale Anticuerpos anti-ADN que penetran en las células y usos de los mismos para inhibir la reparación del ADN
WO2017218824A1 (en) 2016-06-15 2017-12-21 Yale University Anti-guanosine antibody as a molecular delivery vehicle
CA3027960C (en) 2016-06-15 2022-06-14 Yale University Antibody-mediated autocatalytic, targeted delivery of nanocarriers to tumors
AU2020334924A1 (en) * 2019-08-22 2022-04-07 The Regents Of The University Of California UBE3A for the treatment of Angelman syndrome
WO2025018822A1 (ko) 2023-07-20 2025-01-23 제닉스큐어 주식회사 라포라병을 예방 또는 치료하기 위한 재조합 아데노 연관 바이러스 및 이를 포함하는 약학적 조성물
KR102814185B1 (ko) 2023-07-20 2025-06-12 제닉스큐어 주식회사 라포라병을 예방 또는 치료하기 위한 재조합 아데노 연관 바이러스 및 이를 포함하는 약학적 조성물

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BRPI1011236A2 (pt) 2009-06-15 2019-07-09 4S3 Bioscience Inc métodos e composições para tratamento de miopatia miotubular usando polipeptídeos quiméricos compreendendo polipeptídeos miotubularesih 1 (mtm1)
WO2013155476A1 (en) * 2012-04-12 2013-10-17 Integrative Enzymatics, Inc. Composition and method for modulating inflammatory molecules with amylase
CA2901969A1 (en) * 2013-02-20 2014-08-28 Valerion Therapeutics, Llc Methods and compositions for treatment of forbes-cori disease
AU2014218854B2 (en) * 2013-02-20 2019-01-24 Valerion Therapeutics, Llc Methods and compositions for treatment of Pompe disease
JP6709733B2 (ja) * 2014-01-13 2020-06-17 バレリオン セラピューティクス, エルエルシー 内在化部分
WO2015192092A1 (en) * 2014-06-13 2015-12-17 Valerion Therapeutics, Llc Methods and compositions for treatment of glycogen storage diseases and glycogen metabolism disorders
AU2015308894A1 (en) * 2014-08-27 2017-03-23 Valerion Therapeutics, Llc Internalizing moieties for treatment of cancer

Similar Documents

Publication Publication Date Title
JP2019535645A5 (enExample)
JP2012529891A5 (enExample)
JP2011501951A5 (enExample)
US20160031985A1 (en) Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
JP2020511949A5 (enExample)
JP2017527272A5 (enExample)
JP2020531002A (ja) 獣医学用igg fc変異体
MX2020011391A (es) Anticuerpo bcma humanizado y linfocitos t car-bcma.
EP2646472B1 (en) Covalently dimerized bivalent binding agents
RS63149B1 (sr) Insertabilni varijabilni fragmenti antitela i modifikovani a1-a2 domeni nkg2d liganada
RU2007132188A (ru) Конъюгаты биологически активных белков, имеющие модифицированное время полужизни in vivo
JP2019504617A5 (enExample)
CN109563158A (zh) 抗补体因子bb抗体以及其用途
WO2023186120A1 (zh) 抗血清白蛋白纳米抗体及其衍生物
CN107849147A (zh) 基于二泛素突变蛋白的Her2 结合蛋白
US20140271640A1 (en) FGF-10 Complexes
KR20240029769A (ko) 융합단백질 및 이의 응용
WO2014089507A1 (en) Fgf-10 complexes
WO2020093789A1 (zh) 用于改善活性蛋白或多肽性能的人工重组蛋白及其应用
MA32770B1 (fr) Anticorps anti-peptides igf-1/e humain modifie
JP7411264B2 (ja) 新規抗pad2抗体
US8207307B2 (en) Antibodies against human CCN1 and uses thereof
KR20220022899A (ko) 신규 중간체 제조를 통한 지속형 약물 결합체의 제조 방법
Aatsinki et al. An alternative use of basic pGEX vectors for producing both N-and C-terminal fusion proteins for production and affinity purification of antibodies
TW200827441A (en) Method for preparing fusion protein